Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prothena Corporation (PRTA)
:PRTA
Holding PRTA?
Track your performance easily
PRTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.70 - $34.75
Previous CloseN/A
Volume58.73K
Average Volume (3M)651.45K
Market Cap
$709.20M
Enterprise Value$392.14M
Total Cash (Recent Filing)$386.92M
Total Debt (Recent Filing)$51.32M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Feb 13, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding53,808,730
10 Day Avg. Volume452,122
30 Day Avg. Volume651,453
Standard Deviation0.26
R-Squared0.00040
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.35
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit4.29
Enterprise Value/Ebitda-5.86
Forecast
1Y Price Target
$49.75Price Target Upside277.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Prothena News
PremiumCompany Announcements
Prothena Corporation Reports Q3 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe upcoming update on the Phase 1 ascent-2 trial for PRX012 could support a potential best-in-class product profile.
Drug Efficacy And SafetyThe drug was found to be safe and tolerable with no new safety signals, indicating its potential as a reliable treatment option.
Financial StabilityProthena ended the quarter with $529MM in cash, providing a strong foundation to execute on the company's plans.
Bears Say
Clinical TrialsThe Phase 2b PADOVA study evaluating prasinezumab in early-stage Parkinson’s disease did not meet the primary endpoint.
Program UncertaintyThe update creates uncertainty on the future of the program as definitive evidence of clinical benefit is still needed after two failed phase 2 trials.
Regulatory ChallengesThere is a need for 2 large phase 3 trials for registration, which pushes the estimated timelines for the launch of prasinezumab to 2030.
---
Ownership Overview
13.43% Insiders
31.27% Mutual Funds
0.10% Other Institutional Investors
46.24% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRTA FAQ
What was Prothena Corporation’s price range in the past 12 months?
Prothena Corporation lowest stock price was $11.70 and its highest was $34.75 in the past 12 months.
What is Prothena Corporation’s market cap?
Prothena Corporation’s market cap is $709.20M.
When is Prothena Corporation’s upcoming earnings report date?
Prothena Corporation’s upcoming earnings report date is Feb 13, 2025 which is in 26 days.
How were Prothena Corporation’s earnings last quarter?
Prothena Corporation released its earnings results on Nov 12, 2024. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.168 by $0.068.
Is Prothena Corporation overvalued?
According to Wall Street analysts Prothena Corporation’s price is currently Undervalued.
Does Prothena Corporation pay dividends?
Prothena Corporation does not currently pay dividends.
What is Prothena Corporation’s EPS estimate?
Prothena Corporation’s EPS estimate is -1.02.
How many shares outstanding does Prothena Corporation have?
Prothena Corporation has 53,808,730 shares outstanding.
What happened to Prothena Corporation’s price movement after its last earnings report?
Prothena Corporation reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.168. Following the earnings report the stock price went down -0.749%.
Which hedge fund is a major shareholder of Prothena Corporation?
Currently, no hedge funds are holding shares in PRTA
---
Prothena Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.75 (277.47% Upside)
$49.75 (277.47% Upside)
Hedge Fund Trend
Decreased
By 1.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 37.1%
Last 30 Days ▲ 37.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.20%
12-Months-Change
Fundamentals
Return on Equity
-22.90%
Trailing 12-Months
Asset Growth
-20.31%
Trailing 12-Months
Company Description
Prothena Corporation
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
---
PRTA Company Deck
---
PRTA Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook for Prothena, with strong financial results for 2023, substantial advancements in their clinical programs, and a significant collaboration milestone with BMS. However, the increased forecasted cash burn for 2024 and the reliance on future clinical readouts present potential risks.Read More>---
PRTA Stock 12 Month Forecast
Average Price Target
$49.75
▲(277.47% Upside)
Technical Analysis
Axsome Therapeutics
―
ACADIA Pharmaceuticals
―
Allogene Therapeutics
―
Meiragtx Holdings
―
Immatics
―
Fate Therapeutics
―
Best Analysts Covering PRTA
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
-2.82%
reiterated a buy rating last month
Copying Michael Yee's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of -2.82% per trade.
---